Myovant Sciences Ltd. Common Shares (NYSE: MYOV)
On January 23, 2023, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omitted material information with respect to the Proposed Transaction, rendering the Proxy Statement false and misleading. This action seeks damages from Defendants arising from their allegedly false statements in the Proxy.